Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO

On May 2, 2023 Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, reported an abstract detailing new data from its phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma was accepted as an oral presentation in the upcoming American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 26th Annual Meeting in Los Angeles, CA and virtually, May 16-20, 2023 (Press release, Candel Therapeutics, MAY 2, 2023, View Source [SID1234630864]). Additionally, the Company will present a trials-in-progress poster from its phase 2 clinical trial of CAN-2409 plus valacyclovir and anti-PD1 antibodies in patients with stage III/IV non-small cell lung cancer (NSCLC) at the 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 27th Annual Meeting in Chicago, IL and virtually, June 2-6, 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details are as follows:

ASGCT 26th Annual Meeting

Oral Presentation Title: Safety and Survival Outcomes in Recurrent High-Grade Glioma Patients Treated with CAN-3110, a First-in-Class ICP34.5 Expressing Oncolytic HSV1
Presenter: Francesca Barone, MD, PhD, Chief Scientific Officer, Candel Therapeutics
Session Title: Late-Breaking Abstracts 1
Session Date/Time: Friday, May 19, 2023, 8:00 am – 9:45 am PT
Location: Room 515 AB, Los Angeles Convention Center, Los Angeles, CA
ASCO 27th Annual Meeting

Trials-in-Progress Poster Presentation Title: CAN-2409 Plus Prodrug with Standard of Care Immune Checkpoint Inhibitor for Patients with Stage III/IV NSCLC
Presenter: Charu Aggarwal, MD, MPH, Associate Professor for Lung Cancer Excellence, Perelman School of Medicine, University of Pennsylvania
Session Title: Poster Session – Lung Cancer – Non-Small Cell Metastatic
Session Date/Time: Sunday, June 4, 2023, 8:00 am – 11:00 am CT
Location: Hall A, McCormick Place Convention Center, Chicago, IL
Details from the presentations will be available following the events on the Candel website at View Source